L01EX02 · Antineoplastic and immunomodulating agents
Sorafenib Accord
Indications
Hepatocellular carcinomaSorafenib Accord is indicated for the treatment of hepatocellular carcinoma (see section 5.1). Renal cell carcinomaSorafenib Accord is indicated for the treatment of patients with advanced renal cell carcinoma who have failed prior interferon-alpha or interleukin-2 based therapy or are considered unsuitable for such therapy.
Composition
- Active substance
- sorafenib tosilate
- International name (INN)
- sorafenib
Official product information
The European public assessment report holds the summary of product characteristics and the package leaflet in every EU language.
Prognia shows this product information for reference and learning. It is not treatment advice and can lag behind the official text. Always check the current product information and local protocols before prescribing.
At a glance
- Medicine
- Sorafenib Accord
- Active substance
- sorafenib tosilate
- ATC code
- L01EX02